The combination therapy of colistin, artesunate, and EDTA could serve as a promising approach to combat colistin-resistant Salmonella infections by disrupting bacterial membranes, collapsing proton motive force, and increasing reactive oxygen species levels.

Capsular polysaccharides of Acinetobacter baumannii regulate type VI secretion system activity, balancing self-protection with interbacterial competitiveness.